Merck Exit: UK Biopharma Strategy & China’s Rise

Here’s a breakdown of the key points from the ‍provided text:

* Merck’s Shift & China’s Rise: Merck is cutting costs (including scrapping a London research hub and 6,000 global jobs) ⁢not just due to issues in the UK or US, but largely in response to growing competition from Chinese biopharmaceutical companies.
* Keytruda & Ivonescimab: Merck’s blockbuster ⁣drug, Keytruda, faces competition from⁣ a new Chinese drug,⁤ ivonescimab, made by Akeso Biopharma. Ivonescimab outperformed Keytruda in trials and is cheaper. Keytruda’s patent expires in 2028.
* Biopharma vs. Pharma: The industry is shifting ⁢from traditional “pharma” (mass-market drugs) to “biopharma” (bespoke, high-cost therapies).⁢ China is becoming a leader in this biopharma ⁤space.
* UK Impact: ‍The closure of Merck’s UK research center and AstraZeneca’s vaccine ‍research scaling back are setbacks ⁢for the UK’s biopharma ambitions.Industry leaders see the UK as a risky investment, demanding subsidies and relaxed drug pricing regulations.
* Healthcare Trade-offs: Investing heavily in expensive, ⁤niche biopharma treatments means less funding available for broader healthcare needs.
* WHO Listing: The World Health Organization now lists PD-1 drugs (like Keytruda and ivonescimab)⁢ as essential medicines, without‍ giving Keytruda special status.

In essence, the article ‍argues that the global pharmaceutical landscape is ⁢being reshaped by China’s advancements in biopharmaceutical technology, forcing⁢ established companies like Merck to adapt and potentially impacting investment decisions in countries ⁤like the UK.